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Abstract
Cancer-associated-cachexia (CAC) is a ubiquitous characteristic of 
pancreatic cancer (PC) and 1/3 of patients die from its complications. 
Systemic inflammation is key in CAC and the modified Glasgow 
Prognostic Score (mGPS) is a reliable inflammation-based 
prognostic tool. We aimed to evaluate the prognostic value 
of consensus-based cachexia classification and mGPS, their 
agreement and to analyze relevant clinical predictors of cachexia. 
This unicentric, retrospective, cohort study included patients with 
advanced PC treated over a 5-year period. Cachexia was classified 
according to weight loss, body mass index and mGPS. Fisher’s test 
was used to test correlation between classifications and logistic 
regression models were performed to test their association with 
other variables. Survival was analyzed with cox regression and 
Kaplan-Meier curves.
88 eligible patients (mean age 72, 56% female) were reviewed. 
At baseline, cachectic patients (CP) (77%), when compared 
with pre-CP, had worse performance status (p=0.016), more 
NLR>3,5 (p<0.01) and hypoalbuminemia (p 0.01). Of 77% (n=68) 
categorized as cachectic, only 16% (n=8) had a positive mGPS. 
No association was found between classifications (p=0.187). In 
multivariate analysis, NLR>3.5 was a significant predictor of both 
cachexia (p<0.001) and positive mGPS (p<0.01). Median overall 
survival (OS) for pre-CP was 19.1 months vs. 4.9 months in the CP 
(HR 1.94 95% CI 1.10-3.43 p=0.02). A positive mGPS at baseline 
was an independent predictor of worst OS (HR 2.73, 95% CI 1.12-
6.66, p=0.027). 
CAC leads to worst survival and a better understanding of this 
syndrome in PC may improve outcomes for these patients. Our 
study suggests a baseline predominant fat-only loss phenotype, that 
patients with positive mGPS are at higher risk of worst outcomes and 
that NLR is a potential predictor of CAC. A prompt identification of 
prognostic markers may lead to a better standardized management 
of CAC.
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Introduction
Cachexia is defined as a multifactorial syndrome characterized by 
unintended loss of skeletal muscle mass that can be partially, but not 
fully reversed by adequate nutritional support. It presents with a high 
prevalence in cancer patients, mostly in advanced stages of disease [1]. 
Cachexia is nearly omnipresent in patients with pancreatic cancer, 
with an 80% incidence throughout the course of the disease [2-4]. 
Pancreatic adenocarcinoma (PA) is the 7th most common cancer 
in Europe and the 4th cause of death by cancer. 5-year overall survival 
is less than 12 months and in about 30% of patients the cause of 
death is attributed to cachexia-related complications [5,6]. The 
slender association between PA and cachexia might be due to the 
frequent diagnosis in advanced stages and to the direct effects of this 
malignancy in ingestion, digestion and absorption of nutrients [7]. 
The pathophysiology of cachexia is complex, characterized by 
an energetic and protein imbalance, reduced nutrient ingestion and 
an hypercatabolic state [8]. A systemic inflammatory response and 
biochemical alterations (as anemia, rise in c-reactive protein (CRP) 
and hypoalbuminemia) are also key features of this syndrome. It 
is frequent to identify in cachectic patients, symptoms as anorexia, 
reduced muscle strength and fatigue [9]. 
According to a consensus definition from an expert group, 
the definition of cancer-associated cachexia (CAC) relies in the 
presence of at least one of three of the following criteria: weight loss 
(WL) superior to 5% or>2% WL in patients with body mass index 
(BMI)<20 mg/m2 or presence of sarcopenia and WL>2% from 
previous stable weight [10]. The consensus classification suggested 
3 stages of cachexia with clinical relevance: pre-cachexia, defined 
by weight loss of less than 5%, cachexia, defined according to above 
mentioned criteria and refractory cachexia, which relies on clinical 
criteria, with variable degree of cachexia. While refractory cachexia 
implies a very advanced or a rapidly progressive disease, where active 
intervention to reverse WL may not be effective, the other two stages 
offer the prospect of active interventions.
Despite its high prevalence, the establishment of a definition that 
truly reflects the complex pathophysiologic impairments present in 
cachexia was not achieved yet. Furthermore, specific criteria to define 
and stage cachexia remain challenging. 
Most tools to evaluate and stage cachexia are centered in 
evaluating its consequences (weight loss, muscle wasting) and not its 
causes. Despite its importance, WL does not reflect the complexity of 
the pathophysiological impairments present in cachexia. The systemic 
inflammatory response is a crucial trigger of the energetic imbalance 
and muscle wasting that distinguish cachexia. Furthermore, the 
production of inflammatory cytokines by the tumor plays an 
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important role in the acute-phase response, with a rise in CRP and 
a fall in albumin (alb) serum levels [11]. The systemic inflammatory 
response has been proven to have a prognostic value. In this setting, 
different scores and ratios have been validated as prognostic 
predictors (the modified Glasgow Prognostic Score (mGPS), as well 
as neutrophil-lymphocyte ratio (NLR) and platelet-to-lymphocyte 
ratio (PLR)) [12,13]. The most accepted systemic inflammation-based 
score is mGPS, a combined index that evaluates malnourishment and 
inflammation using CRP and alb to define three levels: 0 (CRP≤10 mg/
dL and alb ≥ 3,5 g/dL), 1 (CRP>10 mg/dL) and 2 (CRP>10 mg/dL and 
alb<3,5 gd/L). This score has a prognostic value, validated for cancer 
patients [14,15]. The mGPS Score helps stratify prognosis groups and 
may be a worthy addition to multifactorial evaluations, but as a stand-
alone in individual cases it is unclear at this point how accurate it is 
likely to be. These two approaches to cachexia, a weight based and 
an inflammation based, provide different insights on a truly complex 
and multifactorial syndrome. A simple and practical score as mGPS, 
that can potentially correlate with other variables present in cachexia 
(WL, functional decline, worst performance status, uncontrolled 
symptoms) as well as with survival and that can help in categorizing 
cachexia in different stages and in identifying subset groups at higher 
risk, can be a useful tool in investigating and treating cachexia. 
This study aimed to compare the agreement and prognostic value 
of current cachexia classification (based on weight loss) with the 
systemic inflammation-based mGPS and to evaluate relevant clinical 
predictors of cachexia development. 
Methods
Study design, population and outcomes
This was an observational, descriptive, retrospective cohort 
study performed in a single institution. All patients presenting to the 
Oncology Department of a tertiary hospital, with locally advanced or 
metastatic PA, between the dates of 1 January 2013 and 31 January 
2018 were included. Participants were eligible for enrollment if 
they were aged 18 years or older and had histologically confirmed 
advanced pancreatic adenocarcinoma, defined by the presence of 
distant metastasis, locally advanced disease, either unresectable 
or borderline resectable, that remained unresectable after 
cytoreductive therapy. Patients were excluded if there was lack of 
recorded medical data, lack of available survival data or laboratory 
parameters in clinical files: weight, WL, BMI, albumin and CRP 
serum levels at diagnosis. The primary outcome was overall 
survival (OS), defined as the time of first appointment to death 
from any cause. 
From medical files, demographic and clinical data extracted 
included also age, gender, cancer location in the pancreas, Eastern 
Cooperative Oncology Group (ECOG)/performance status (PS) at 
diagnosis, systemic anticancer treatments, loss of appetite, reported 
by patients, and also readily available serum markers of inflammation, 
not only CRP and albumin, but also NLR and PLR, calculated from 
routine full blood neutrophil, lymphocyte and platelet count results, 
as a simple ratio between absolute counts. 
Cachexia assessment
Patients were categorized as having cachexia according to two 
definitions. The first one was based on consensus definition [16] 
and incorporated WL and BMI. Consensus definition categorizes 
patients in 3 stages, being that the most advanced one, refractory 
cachexia, is defined by clinical criteria. In order to better assess WL 
among cachectic patients and detect any relevant changes in these 
population, we’ve subdivided WL into 2 categories. Patients with 
unintended weight loss≥5% during last 6 months were classified as 
precachectic, as in the consensus, patients with>5% to 10% weight 
loss or low BMI<20 kg/m2 and ongoing weight loss>2%-10% as 
cachectic and patients with>10% weight loss as severe cachectic. The 
second classification was the mGPS score: 0 defined by CRP≤10 mg/
dL and alb≥3,5 g/dL), 1 by CRP>10 mg/dL and 2 by CRP>10 mg/dL 
and alb<3,5 g/dL.
Data on Body Mass Index and weight loss
Data on pre-illness weight and time of weight loss were self-
reported by patients. Baseline weight and height were collected 
by clinicians in the first oncology appointment. To calculate the 
percentage of weight loss, we used the following equation: (pre-illness 
weight – current weight) x 100/pre-illness weight. BMI was calculated 
from weight and height (kg/m2).
Statistical analysis
Data analysis of patient baseline demographic and clinical 
characteristics was performed using absolute and relative frequencies 
for categorical variables and central tendency, dispersion and range 
for continuous variables, according to mGPS and cachexia stages. 
Univariate association of characteristics with student’s t-test and 
Kruskal-Wallis test was performed, according to data distribution. 
A comparison between the cachexia classification and mGPS score 
was done using a 2 x 2 contingency table and Fisher’s exact test. A 
univariate single-factor logistic regression analyses was performed to 
assess effect of markers of inflammation, using maximum-likelihood 
estimation. According to standard cut-offs, NLR >3.5 and PLR>150 
were tested. We also conducted multivariate logistic regression 
analysis with forward delection and likelihood ratio test (LRT). For 
each factor, we calculated the adjusted odds ratio and 95% CI using 
maximum likelihood estimation. Overall survival plots were built 
using Kaplan–Meier methods, according to mGPS and cachexia 
stages. Univariate differences between survival rates were tested for 
significance using the log-rank test. Cox proportional hazards models 
(estimated HRs and 95% CIs) was used to study the association 
between potential prognostic factors and outcomes. All analysis were 
performed using SPSS version 26 software. All results with a p value 
less than 0.05 were considered statistically significant.
Results
We’ve included 88 patients, with a mean age of 72 years, 56% (n=49) 
females. Most patients in pre-cachectic group received chemotherapy 
(75%), differently from patients in cachectic and refractory cachectic 
groups, where less than half (48%) underwent this treatment regimen. 
Most precachectic patients had good performance status, with 85% 
patients with ECOGPS 0-1, contrarily to patients with some degree of 
cachexia, with close to a third classified as ECOG/PS 3. Precachectic 
patients had significantly lower NLR (p<0.01), compared to patients 
with some degree of cachexia. An NLR>3.5 was present in 10% 
(n=2) precachectic patients and in 58% (n=25) patients with severe 
cachexia. Also, PLR was higher for cachectic patients when compared 
to prechachectic (p=0.06). Serum values, of hemoglobin (p=0.035) 
and albumin (p<0.01) were also notably lower in patients with 
cachexia. All baseline demographics and disease characteristics are 
presented in Table 1 for the classification according with consensus-
based definition for cachexia and (Table 2) presents classification 
according to mGPS. 
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Association between Cancer Associated Cachexia and 
Modified Glasgow Prognostic Score classifications
Based on classification of CAC, 23% (n=20) patients were 
categorized as pre-cachectic and 77% (n=68) as cachectic or severe 
cachectic. Using baseline Albumin and CRP values, mGPS index was 
calculated, resulting in the identification of 84% (n=66) with mGPS 
of 0 and 16% (n=8) with mGPS of 1 or 2, so the majority of patients 
classified as cachectic had no change in mGPS at baseline. There was 
no association between the classification of patients as cachectic or 
non-cachectic according to consensus definition and mGPS being 
positive or zero (p=0.187). Specifically, 48 individuals that had been 
diagnosed with cachexia presented a score of 0, representing a 65% 
mismatch in outcome. Despite no association, all individuals with a 
positive mGPS were cachectic and 18 individuals who had not been 
diagnosed with cachexia presented scores of 0, meaning that 35% of 
all individuals had matching outcomes.
Predictors of cachexia development
Multivariate analyses with stepwise delection, using sex, age, 
NLR>3.5 and PLR>3.5, showed that an NLR>3.5 was associated 
with cachexia development (Table 3), after stepwise procedure (LRT 
16.729, p<0.001). Univariate analysis was also performed and showed 
concordant results. When applying the same analysis with dependent 
variable being mGPS results, also only NLR>3.5 was statistically 







0.44Male 11 (55.0) 9 (36.0) 19 (44.2)
Female 9 (45.0) 16 (64.0) 24 (55.8)
Age (Years) 69.1 (20) 76.1 (17) 76.3 (15) 0.42
Previous Weight (kg) 66.5 (14) 66.0 (11) 72.0 (18) 0.07
Weight at diagnosis (kg) 65.5 (15) 60.0 (12) 60.0 (18) 0.12
Height (cm) 160.5 (11) 161.0 (9) 160.0 (11) 0.88
% Weight Loss in past 6 months 0.0 (0) 7.7 (2.1) 15.7 (6.8) <0.01
Body Mass Index at diagnosis 24.3 (6.2) 23.4 (4.6) 22.1 (5.2) 0.03
Body Mass Index (BMI)
-
Obese (BMI ≥30) 4 (20) 0 (0) 2 (4.6)
Overweight (25<BMI<30) 5 (25) 7 (28) 9 (21)
Normal (20<BMI<25) 10 (50) 15 (60) 24 (55.8)
Risk of malnutrition (BMI<20) 1 (5) 3 (12) 8 (18.6)
Loss of appetite 1 (4.0) 20 (80.0) 34 (79.1) <0.01
Chemotherapy 15 (75.0) 12 (48.0) 21 (48.8) 0.11
ECOG Performance Status (PS)
0.016
ECOG/PS 0 9 (45) 5 (20) 9 (21)
ECOG/PS 1 8 (40) 10 (40) 14 (33)
ECOG/PS 2 2 (10) 3 (12) 10 (23)
ECOG/PS 3 1 (5) 7 (28) 9 (21)
ECOG/PS 4 0 (0) 0 (0) 1 (2)
Neutrophil to Lymphocyte Ratio (NLR) 2 (1.67) 6 (5.75) 4 (4.0)
<0.01
NLR>3.5 2 (10) 13 (52) 25 (58)
Platelet to lymphocyte ratio (PLR) 117 (60.6) 140 (100.3) 163.7 (112.2)
0.06
PLR>150 6 (30) 11 (44) 21 (48.8)
Hemoglobin (g/dL) 12.5 (1.7) 11.0 (2.1) 11.2 (2.9) 0.01
C Reactive Protein (CRP) (mg/dL) 1.8 (4.0) 3.6 (14.9) 2.8 (3.9) 0.035
CRP>10 1 (5) 8 (32) 0 (0)
Albumin (g/dL) 3.8 (1.0) 2.6. (1.0) 3.2 (0.9) <0.01
Albumin<3,5 8 (40) 17 (68) 19 (44)








1.0Male 33 (50.0) 0 (0.0) 3 (42.9)
Female 33 (50.0) 1 (100.0) 4 (57.1)
Age (Years) 72.6 (15) - 81.9 (18) -
Baseline Weight Loss 11.0 (12.6) - 7.7 (1.6) -
Table 2: Demographic characteristics baseline, according to mGPS classification. Data are median (IQR) or n (%).
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Survival results
After a median follow-up of 6.9 (IQR 2.7–16.5) months, 77 
patients (87.5%) died: 61 (69.3%) vs. 16 (18.2%) in cachectic and non-
cachectic groups, respectively. Patients without cachexia tended to 
live longer, with a median survival of 19.1 months, compared to a 
median survival of 4.9 months of those patients without cachexia. In 
line with this difference, a statistical tendency was noted disfavoring 
patients with cachexia, both in the univariate (p<0.01) and 
multivariate analysis (controlling for age at diagnosis and ECOG/PS; 
HR 1.94, 95% CI 1.10-3.43, p=0.02) (Figure 1). 
When analyzing patients according to mGPS, all 8 (100%) patients 
with a positive mGPS died, vs. 55 (87%) patients dying with an mGPS 
of 0. A positive mGPS was markedly correlated with worse survival, 
both in univariate (p<0.01) and multivariate analysis (adjusting for 







Table 3: Results of the multivariate logistic regression model for cachexia, based on Sex, Age, NLR and PLR. Presented are the Likelihood ratio test results for each 
variable and respective p-value. LRT: Likelihood Ratio Test; NLR: Neutrophil to Lymphocyte Ratio; PLR: Platelet to Lymphocyte Ratio.
Figure 1: Overall survival according to Cachexia at diagnosis. Multivariate analysis controlling for age at diagnosis and ECOG/PS.
Figure 2: Overall survival according to mGPS at diagnosis. Multivariate analysis controlling for age at diagnosis and ECOG/PS.
Citation: Cardoso D, Matos LV, Fernandes L, Domingues TD, João R, et al. (2020) Pancreatic Cancer Associated-Cachexia: Role of the Modified Glasgow 
Prognostic Score in Outcome Prediction. J Clin Exp Oncol 9:1.
• Page 5 of 5 •Volume 9 • Issue 1 • 1000241
Discussion
PA is an illness with high morbidity and mortality and a great 
majority of patients with PA will present with cachexia at diagnosis. 
CAC is still largely misunderstood due to its complex physiopathology 
and, unfortunately, no treatment has so far proven to be successful. 
Despite extensive efforts, there remains an urgent need to identify 
reliable and routinely available prognostic factors. 
In this retrospective study we aimed to assess the correlation 
between consensus-based definition of CAC with the validated 
inflammatory score mGPS and to study relevant clinical predictors 
of changes with each tool Since cachexia stages are defined according 
to % of WL alone or together with BMI and mGPS is a score based 
on inflammatory parameters (albumin and CRP), patient’s baseline 
classification according to CAC definition and mGPS score suggest 
that, at diagnosis, fat loss prevails over muscle loss. These results are 
in line with the theory postulated by the international consensus, of a 
disease continuum in which early stages are characterized mainly by 
anorexia and impaired glucose tolerance, which precede substantial 
involuntary WL [17]. 
The mGPS score has shown to be a useful aid to stratify risk 
groups and better characterize the inflammatory component of CAC. 
We therefore interrogated whether, at diagnosis of PA, mGPS score 
could be correlated with presence of absence of CAC, according to 
standard definition. In our cohort, we showed no association between 
classifications but a relevant positive predictive tendency, since all 
patients with positive mGPS were cachectic. 
Regarding CAC predictors, in our study we’ve incorporated other 
relevant markers of inflammation, the NLR and PLR, which combine 
neutrophil, lymphocyte and platelet levels in peripheral venous 
blood. These quantifications have been found to have predictive value 
in early diagnosis and malignancies as pancreatic cancer and can 
reflect prognosis in some extend, while being cost-effective [18]. In 
our cohort, using NLR clinically relevant cuf-off of 3.5, an NLR>3.5 
showed to be a significant predictor of CAC at diagnosis and positive 
mGPS at diagnosis. These results further validate the predictive role 
of NLR in identifying at-risk patients of CAC at PA diagnosis: on 
average, a patient will over 13.5 times more likely to be diagnosed as 
cachectic if the NLR is>3.5. 
Previous studies have already showed the negative impact 
of cachexia in survival [19, 20] and our results corroborate these 
findings. Patients with cachexia lived, in median, less 14.2 months 
than patients with no cachexia. When survival was calculated 
according to mGPS score, and adjusted for covariates in multivariate 
analysis, it showed a significantly worse prognosis for patients with a 
positive mGPS, compared with patients with mGPS of 0.
Conclusion
The results of this study help to shed light in this underappreciated 
but deathly syndrome that affects more than 80% of PA patients. 
While mGPS should not be used as a stand-alone tool, it can 
relevantly identify a patient’s subgroup at higher risk for worst 
outcomes, Likewise, NLR should be assessed at diagnosis of PA and 
a value>3.5 act as a trigger for a multimodal approach to CAC. A 
complete evaluation of multiple cachexia domains is important not 
only to better understand the complete landscape of CAC, but also 
to potentially identify treatment strategies to reverse it. Multimodal 
treatments, targeting the different domains of cachexia have shown 
promising. Better knowledge on cachexia and the complex web 
that links this syndrome to PA may prompt the design of targeted 
therapies that are able to ameliorate wasting in cachectic patients, 
with reflections in an improvement of quality of life and survival.
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